[Neurochemical markers of neurodegeneration in the early diagnosis of Alzheimer's disease, vascular and mixed dementia].
A study of 27 patients with dismnestic variant of moderate cognitive impairment (MCI) and 20 patients with neurodynamic-dysregulatory variant was carried out. The more intensive atrophic process supported by neuroimaging data and changed levels of neurodegeneration biomarkers - phosphorylated tau-protein 181 and beta-amyloid 42 - were found in patients with dismnestic MCI variant. The follow-up study showed that the large number of patients with progressive cognitive disorders associated with conversion to dementia was observed in this group. In conclusion, the determination of the neurochemical markers in the cerebrospinal fluid allows to detect the neurodegenerative process at early stages of the disease and assists in detection of cases with increased risk of Alzheimer's disease.
Uspenskaia
O V
OV
Iakhno
N N
NN
Belushkina
N N
NN
D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000175:diagnosis*; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D015415:Biomarkers / Q000134:cerebrospinal fluid; D003072:Cognition Disorders / Q000134:cerebrospinal fluid / Q000175:diagnosis*; D015140:Dementia, Vascular / Q000134:cerebrospinal fluid / Q000175:diagnosis*; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D008297:Male; D019636:Neurodegenerative Diseases / Q000134:cerebrospinal fluid / Q000175:diagnosis*; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D016875:tau Proteins / Q000134:cerebrospinal fluid*
D016229:Amyloid beta-Peptides; D015415:Biomarkers; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D016875:tau Proteins